These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

465 related articles for article (PubMed ID: 33904521)

  • 21. Aldosterone Rapidly Enhances Levels of the Striatin and Caveolin-1 Proteins in Rat Kidney: The Role of the Mineralocorticoid Receptor.
    Inthachart K; Manotham K; Eiam-Ong S; Eiam-Ong S
    Endocrinol Metab (Seoul); 2019 Sep; 34(3):291-301. PubMed ID: 31565882
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Eplerenone: a selective aldosterone receptor antagonist for hypertension and heart failure.
    Moore TD; Nawarskas JJ; Anderson JR
    Heart Dis; 2003; 5(5):354-63. PubMed ID: 14503934
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical implications of aldosterone blockade.
    Weber MA
    Am Heart J; 2002 Nov; 144(5 Suppl):S12-8. PubMed ID: 12422136
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Striatin Gene Variants Are Associated With Salt Sensitivity of Blood Pressure by Mechanisms That Differ in Women and Men.
    Gholami SK; Heydarpour M; Williams JS; Pojoga LH; Adler GK; Williams GH; Romero JR
    Hypertension; 2024 Feb; 81(2):330-339. PubMed ID: 38018471
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Unanticipated increases in hepatic steatosis among human immunodeficiency virus patients receiving mineralocorticoid receptor antagonist eplerenone for non-alcoholic fatty liver disease.
    Chaudhury CS; Purdy JB; Liu CY; Morse CG; Stanley TL; Kleiner D; Hadigan C
    Liver Int; 2018 May; 38(5):797-802. PubMed ID: 29509992
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and safety of mineralocorticoid receptors in mild to moderate arterial hypertension.
    Pelliccia F; Rosano G; Patti G; Volterrani M; Greco C; Gaudio C
    Int J Cardiol; 2015 Dec; 200():8-11. PubMed ID: 25466561
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes.
    Epstein M; Williams GH; Weinberger M; Lewin A; Krause S; Mukherjee R; Patni R; Beckerman B
    Clin J Am Soc Nephrol; 2006 Sep; 1(5):940-51. PubMed ID: 17699311
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical safety, tolerability, pharmacokinetics and effects on urinary electrolyte excretion of AZD9977, a novel, selective mineralocorticoid receptor modulator.
    Erlandsson F; Albayaty M; Chialda L; Ericsson H; Amilon C; Nelander K; Jansson-Löfmark R; Wernevik L; Kjaer M; Bamberg K; Hartleib-Geschwindner J
    Br J Clin Pharmacol; 2018 Jul; 84(7):1486-1493. PubMed ID: 29468715
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A Comparison of Adrenalectomy and Eplerenone on Vascular Function in Patients with Aldosterone-producing Adenoma.
    Kishimoto S; Oki K; Maruhashi T; Kajikawa M; Hashimoto H; Takaeko Y; Harada T; Yamaji T; Han Y; Kihara Y; Chayama K; Goto C; Yusoff FM; Nakashima A; Higashi Y
    J Clin Endocrinol Metab; 2020 Nov; 105(11):. PubMed ID: 32818224
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Long-term safety and efficacy of the selective aldosterone blocker eplerenone in patients with essential hypertension.
    Burgess ED; Lacourcière Y; Ruilope-Urioste LM; Oparil S; Kleiman JH; Krause S; Roniker B; Maurath C
    Clin Ther; 2003 Sep; 25(9):2388-404. PubMed ID: 14604739
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension.
    Weinberger MH; Roniker B; Krause SL; Weiss RJ
    Am J Hypertens; 2002 Aug; 15(8):709-16. PubMed ID: 12160194
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The effect of aldosterone and aldosterone blockade on the progression of chronic kidney disease: a randomized placebo-controlled clinical trial.
    Minakuchi H; Wakino S; Urai H; Kurokochi A; Hasegawa K; Kanda T; Tokuyama H; Itoh H
    Sci Rep; 2020 Oct; 10(1):16626. PubMed ID: 33024237
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Anti-albuminuric effect of the aldosterone blocker eplerenone in non-diabetic hypertensive patients with albuminuria: a double-blind, randomised, placebo-controlled trial.
    Ando K; Ohtsu H; Uchida S; Kaname S; Arakawa Y; Fujita T;
    Lancet Diabetes Endocrinol; 2014 Dec; 2(12):944-53. PubMed ID: 25466242
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of eplerenone on blood pressure and the renin-angiotensin-aldosterone system in oligo-anuric chronic hemodialysis patients - a pilot study.
    Shavit L; Neykin D; Lifschitz M; Slotki I
    Clin Nephrol; 2011 Nov; 76(5):388-95. PubMed ID: 22000559
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Determinants of blood pressure reduction by eplerenone in uncontrolled hypertension.
    Jansen PM; Frenkel WJ; van den Born BJ; de Bruijne EL; Deinum J; Kerstens MN; Arnoldus JH; Woittiez AJ; Wijbenga JA; Zietse R; Danser AH; van den Meiracker AH
    J Hypertens; 2013 Feb; 31(2):404-13. PubMed ID: 23249826
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The role of ambulatory blood pressure monitoring compared with clinic and home blood pressure measures in evaluating moderate versus intensive treatment of hypertension with amlodipine/valsartan for patients uncontrolled on angiotensin receptor blocker monotherapy.
    Giles TD; Oparil S; Ofili EO; Pitt B; Purkayastha D; Hilkert R; Samuel R; Sowers JR
    Blood Press Monit; 2011 Apr; 16(2):87-95. PubMed ID: 21386706
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mineralocorticoid Receptor Activation Contributes to the Supine Hypertension of Autonomic Failure.
    Arnold AC; Okamoto LE; Gamboa A; Black BK; Raj SR; Elijovich F; Robertson D; Shibao CA; Biaggioni I
    Hypertension; 2016 Feb; 67(2):424-9. PubMed ID: 26644241
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Double-Blind Randomized Phase 3 Study Comparing Esaxerenone (CS-3150) and Eplerenone in Patients With Essential Hypertension (ESAX-HTN Study).
    Ito S; Itoh H; Rakugi H; Okuda Y; Yoshimura M; Yamakawa S
    Hypertension; 2020 Jan; 75(1):51-58. PubMed ID: 31786983
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The use of plasma aldosterone and urinary sodium to potassium ratio as translatable quantitative biomarkers of mineralocorticoid receptor antagonism.
    Eudy RJ; Sahasrabudhe V; Sweeney K; Tugnait M; King-Ahmad A; Near K; Loria P; Banker ME; Piotrowski DW; Boustany-Kari CM
    J Transl Med; 2011 Oct; 9():180. PubMed ID: 22017794
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Eplerenone prevents salt-induced vascular remodeling and cardiac fibrosis in stroke-prone spontaneously hypertensive rats.
    Endemann DH; Touyz RM; Iglarz M; Savoia C; Schiffrin EL
    Hypertension; 2004 Jun; 43(6):1252-7. PubMed ID: 15117913
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.